ScreenerHero

NVAXNovavax, Inc.

NAS · US · Healthcare · Biotechnology · novavax.com
8.940USD+1.71%Mkt Cap: 1.47B $P/E: —

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company comme…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.47B $
Enterprise Value966.82M $
Revenue (TTM)413.80M $
Gross Profit1.05B $
Net Income (TTM)440.30M $
Revenue/Share2.536 USD
Last Price8.940 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees749
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6700024010
Valuation
P/E (Trailing)—
P/E (Forward)-13.72
PEG1.32
EV/EBITDA-9.52
EV/Revenue2.34
P/S3.36
P/B-7.28
EPS (TTM)-1.47
EPS (Forward)-0.61
52W Range
6.20047% of range11.97
52W High11.97 USD
52W Low6.200 USD
Profitability
Gross Margin93.50%
Oper. Margin-89.61%
EBITDA Margin-24.54%
Profit Margin39.19%
ROE-344.65%
ROA37.42%
Growth
Revenue Growth-76.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-244.63M $
CapEx (TTM)6.39M $
FCF Margin37.07%
FCF Yield10.40%
Net Debt-422.02M $
Net Debt/EBITDA4.16
Balance Sheet
Debt/Equity-1.95
Current Ratio2.33
Quick Ratio2.23
Book Value/Sh-1.1570 USD
Cash/Share4.361 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 10, 2019
Splits
Last Split1:20
Split DateMay 10, 2019
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.00 USD
Upside (mean)+56.6%
Target Range7.000 USD – 25.00 USD
$7.000+56.6% to mean$25.00
# Analysts9
Ownership
Shares Out.164.95M
Float142.52M
Insiders5.06%
Institutions69.04%
Short Interest
Short Ratio13.8d
Short % Float27.86%
Short % Out.27.68%
Shares Short45.66M
Short (prev mo.)45.81M
Technical
SMA 508.454 (+5.7%)
SMA 2008.431 (+6.0%)
Beta2.42
S&P 52W Chg18.16%
Avg Vol (30d)3.56M
Avg Vol (10d)4.12M
Technical Indicators
RSI (14)67.1
MACD0.0258
MACD Signal-0.1557
MACD Hist.+0.1815
BB Upper8.713 USD
BB Middle7.825 USD
BB Lower6.936 USD
BB Width22.71%
ATR (14)0.3917 USD
Vol Ratio (20d)3.04x